TY - JOUR
T1 - Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis
AU - Hardan, Izhar
AU - Rothman, Rachel
AU - Gelibter, Alain
AU - Cohen, Ninette
AU - Shimoni, Avichai
AU - Sokolovsky, Maya
AU - Reichart, Malka
AU - Ishoev, Galina
AU - Amariglio, Ninette
AU - Rechavi, Gideon
AU - Nagler, Arnon
AU - Trakhtenbrot, Luba
PY - 2004/3
Y1 - 2004/3
N2 - Deletion of chromosome 13q is believed to be an adverse prognostic marker in patients with multiple myeloma (MM). Interphase fluorescence in situ hybridization (I-FISH) is the method of choice for detection of chromosome 13q deletion (del13q). However, I-FISH has high false-positive rates attributed to a low percentage of plasma cells (PC), which are responsible for MM, in bone marrow (BM) samples from MM patients. In an attempt to overcome this problem, combined morphologic and I-FISH analyses were performed by a unique system that allows rapid automatic scanning of a large number of cells with simultaneous determination of the lineage of specific cells carrying del13q. The percentage of PC with del13q in BM samples from 40 MM patients was calculated. In addition, we established a useful prognostic ratio defined as the number of PC with del13q divided by the number of non-PC with del13q (PDP/PDNP), which may help to precisely define the putative role of del13q in prediction response of MM patients to new therapeutic compounds. We suggest this technique as a novel sensitive and specific method for detection of del13q in a minor PC population of MM patients.
AB - Deletion of chromosome 13q is believed to be an adverse prognostic marker in patients with multiple myeloma (MM). Interphase fluorescence in situ hybridization (I-FISH) is the method of choice for detection of chromosome 13q deletion (del13q). However, I-FISH has high false-positive rates attributed to a low percentage of plasma cells (PC), which are responsible for MM, in bone marrow (BM) samples from MM patients. In an attempt to overcome this problem, combined morphologic and I-FISH analyses were performed by a unique system that allows rapid automatic scanning of a large number of cells with simultaneous determination of the lineage of specific cells carrying del13q. The percentage of PC with del13q in BM samples from 40 MM patients was calculated. In addition, we established a useful prognostic ratio defined as the number of PC with del13q divided by the number of non-PC with del13q (PDP/PDNP), which may help to precisely define the putative role of del13q in prediction response of MM patients to new therapeutic compounds. We suggest this technique as a novel sensitive and specific method for detection of del13q in a minor PC population of MM patients.
UR - http://www.scopus.com/inward/record.url?scp=12144285692&partnerID=8YFLogxK
U2 - 10.1016/j.exphem.2003.12.001
DO - 10.1016/j.exphem.2003.12.001
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 15003310
AN - SCOPUS:12144285692
SN - 0301-472X
VL - 32
SP - 254
EP - 260
JO - Experimental Hematology
JF - Experimental Hematology
IS - 3
ER -
